FATE Q3 2022 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+5.3% YoY

Gross Profit

-$65M-432.8% margin

Operating Income

-$86M-576.7% margin

Net Income

-$84M-557.8% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-19.2%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$64M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$749M

Total Liabilities

$231M

Stockholders' Equity

$518M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$14M	+5.3%
Gross Profit	-$65M	-$39M	-66.7%
Operating Income	-$86M	-$55M	-58.2%
Net Income	-$84M	-$43M	-93.0%

Revenue Segments

Upfront Fee And Equity Premium

$4M100%